Abstract
Hypertension is one of the major health care problems worldwide since it markedly increases the risk for development of heart disease, stroke, generalized vascular disease, and renal failure. The renin–angiotensin system (RAS) with its major end-product angiotensin II (Ang II) plays a fundamental role in blood pressure regulation through direct and indirect mechanisms. Pharmacologically, we can inhibit the RAS using angiotensin-converting enzyme inhibitors and AT1 receptor blocker. Inhibiting renin directly with a clinically useful drug eluded pharmacologists until recently. However, the once-daily, orally effective, small-molecule, direct renin inhibitor aliskiren has recently changed this state of affairs. Aliskiren, with its 40-h half-life and ideal pharmacokinetics, can now address angiotensin production directly at its rate-limiting step. A novel transgenic rat model outfitted with the human renin and angiotensinogen genes allowed the testing of aliskiren in an animal model. Preclinical data demonstrated that aliskiren prolonged survival, decreased cardiac hypertrophy and the inducibility of arrhythmias, proteinuria, and attenuated inflammation. All these features might result in improved target-organ damage. Studies in humans attest to an effective blood pressure-lowering action, a largely side effect-free profile, and the option of several combination therapies. Aliskiren is the first of a novel antihypertensive drug class. The preclinical data is very promising. Nevertheless, for the evaluation of its potency in humans, we have to wait for more clinical data.
Similar content being viewed by others
References
Azizi M (2006) Renin inhibition. Curr Opin Nephrol Hypertens 15(5):505–510
Muller DN, Luft FC (2006) Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 1(2):221–228
Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH (1997) Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 10(1):1–8
Kehoe B, Keeton GR, Hill C (1986) Elevated plasma renin activity associated with renal dysfunction. Nephron 44(1):51–57
Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T (2002) Relationships between left ventricular mass and the renin–angiotensin system, catecholamines, insulin and leptin. J Intern Med 252(5):430–439
Alderman MH, Cohen HW, Sealey JE, Laragh JH (2004) Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 17(1):1–7
Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F, Ruf P, Hilgenfeldt U, Ganten U, Kaling M, Bachmann S, Fukamizu A, Mullins J, Murakami K (1992) Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 89(16):7806–7810
Wellner M, Dechend R, Park JK, Shagdarsuren E, Al-Saadi N, Kirsch T, Gratze P, Schneider W, Meiners S, Fiebeler A, Haller H, Luft FC, Muller DN (2005) Cardiac gene expression profile in rats with terminal heart failure and cachexia. Physiol Genomics 20(3):256–267
Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Muller DN (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46(3):569–576
Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, Dechend R, Gratze P, Luft FC, Muller DN (2005) Complement activation in angiotensin II-induced organ damage. Circ Res 97(7):716–724
Dechend R, Shagdarsuren E, Gratze P, Fiebeler A, Pilz B, Meiners S, Derer W, Feldman DL, Webb R, Muller DN (2007) Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. J Renin Angiotensin Aldosterone Syst 8(2):81–84
Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, Herse F, Park JK, Gapelyuk A, Schwarz I, Zacharzowsky UB, Plehm R, Safak E, Heuser A, Schirdewan A, Luft FC, Schunck WH, Muller DN (2008) Dietary n−3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 51(2):540–546
Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Muller DN (2005) Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111(23):3087–3094
Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC (2001) Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 37(2 Part 2):787–793
Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC (2004) Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109(22):2792–2800
Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39(1):E1–E8
Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50(11):2398–2404
Ambuhl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, Pfister T, Rettenbacher M, Volk HD, Wagner F, Muller P, Jennings GT, Bachmann MF (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25(1):63–72
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Müller, D.N., Derer, W. & Dechend, R. Aliskiren—mode of action and preclinical data. J Mol Med 86, 659–662 (2008). https://doi.org/10.1007/s00109-008-0330-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-008-0330-6